Where I see patients (2)
My reviews
Selected research
-
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
European urology
-
Modulating the PPAR? pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
Nature communications
-
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
The oncologist
4.9